Key Takeaways
- Sector: Biotechnology & Life Sciences.
- Geography: United States.
Analysis
Permira has initiated the sale of US-based contract drugmaker Cambrex, aiming for a valuation of up to $4 billion. The move comes as demand for domestic pharmaceutical manufacturing continues to soar, driven by global supply chain realignment and geopolitical shifts.
The UK-headquartered private equity firm acquired Cambrex in 2019 for around $2.4 billion and has since scaled the company across North America and Europe. Cambrex provides full-lifecycle drug development services, and its extensive US footprint has positioned it as a strategic asset amid growing reshoring initiatives.
Cambrex generates approximately $225 million in adjusted EBITDA and operates 14 facilities worldwide, with a strong emphasis on small-molecule drug production, quality control, and regulatory support. The company has been a major beneficiary of policies encouraging domestic production in the United States.
Permira’s expected divestment joins a wave of recent large-scale transactions in the space. In 2024, PCI Pharma Services was valued at $10 billion following a strategic investment from Bain Capital and Kohlberg & Co., signaling high investor confidence in pharmaceutical outsourcing platforms.
Another landmark deal was Novo Holdings’ $16.5 billion acquisition of Catalent, which included the transfer of three fill-finish facilities to Novo Nordisk for $11 billion. This transaction emphasized the critical value of manufacturing infrastructure for biologics and injectables.
Additionally, Advent International and Warburg Pincus backed the $6 billion merger of BioAgilytix and Syneos Health’s lab division in 2023, further highlighting the growing interest in end-to-end service providers catering to biotech and pharma clients.
Permira is reportedly engaging a dozen private equity sponsors through financial advisors, targeting both sector specialists and large global buyout firms. However, the firm may decide to hold Cambrex if offers fall short of valuation expectations.
The proposed transaction underscores the growing importance of domestic pharmaceutical manufacturing not only in the United States but also across Europe and Asia, where governments are boosting investment in healthcare infrastructure to ensure supply chain sovereignty.
With Permira managing €85 billion (approximately $99.5 billion) in assets and recently partnering with Nordic Capital on a $3 billion bid for Bavarian Nordic, the firm continues to show strategic intent in high-growth, defensible healthcare assets.